AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/article-1G1-137211658/mefloquine-revised-patient-information.html" title="Facts and information about Mefloquine: revised patient information.(Safety and Efficacy Issues)">Mefloquine: revised patient information.(Safety and Efficacy Issues)</a>
Close
Set up an RSS feed that alerts you when new articles from WHO Drug Information are available.
Frequently asked questions about RSS feeds
Mefloquine: revised patient information.(Safety and Efficacy Issues)
Canada -- Health Canada has advised of the availability of revised patient information for prophylactic use of the antimalarial, mefloquine (Apo-Mefloquine[R]).
The warnings and contraindications sections have been modified to inform of:
* rare events that may occur with the use of Apo-Mefloquine, including anxiety, paranoia, depression, hallucinations, and psychotic behaviour; as well as suicidal ideation and suicide, for which …
Related articles from newspapers, magazines, journals, and more
-
- Quinidine (Systemic).
-
USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language
May 1, 2006
700+ words
-
- SULFONAMIDE AND TRIMETHOPRIM COMBINATION (Oral route, Parenteral route).(Drug...
-
USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language
May 1, 2007
700+ words
